UBS AM
ABEO icon

UBS AM’s Abeona Therapeutics ABEO Stock Holding History

UBS AM’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.1K Hold
3,412
– – ﹤0.01% 3120
2026
Q1 		$15.3K Buy
3,412
+3,278
+2,446% +$16.4K ﹤0.01% 3201
2025
Q4 		$706 Buy
+134
New +$675 ﹤0.01% 3215
2019
Q4 		– Sell
-1,979
Closed -$112K – 2537
2019
Q3 		$112K Buy
+1,979
New +$148K ﹤0.01% 2653
2018
Q4 		– Sell
-763
Closed -$244K – 2771
2018
Q3 		$244K Hold
763
– – ﹤0.01% 2354
2018
Q2 		$305K Buy
+763
New +$333K ﹤0.01% 2293

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OIA
OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS AM's ABEO Position: Q2 2026 in Review

UBS AM held its Abeona Therapeutics (ABEO) position steady in Q2 2026 at 3,412 shares worth $21.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3120.

UBS AM first reported a position in ABEO in Q2 2018 and has held it in 6 quarters since. The position peaked at $305K in Q2 2018. 127 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

  • UBS AM held 3,412 shares of Abeona Therapeutics worth $21.1K as of Q2 2026.
  • UBS AM left its Abeona Therapeutics share count unchanged in Q2 2026.
  • Abeona Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3120 holding.
  • UBS AM first reported a position in Abeona Therapeutics in Q2 2018 and has held it in 6 quarters since.
  • UBS AM's Abeona Therapeutics position peaked at $305K in Q2 2018.
  • 127 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.